To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Use of theragnostic marke… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease.

Review article
Authors Henrik Zetterberg
Niklas Mattsson
Kaj Blennow
Bob Olsson
Published in Alzheimer's research & therapy
Volume 2
Issue 6
Pages 32
ISSN 1758-9193
Publication year 2010
Published at Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Pages 32
Language en
Links dx.doi.org/10.1186/alzrt56
Subject categories Psychiatry

Abstract

ABSTRACT: In a slowly progressive disorder like Alzheimer disease, evaluation of the clinical effect of novel drug candidates requires large numbers of patients and extended treatment periods. Current cell- and animal-based disease models of Alzheimer disease are poor at predicting a positive treatment response in patients. To help bridge the gap between disease models and large and costly clinical trials with high failure rates, biomarkers for the intended biochemical drug effect may be of value. Such biomarkers may be called 'theragnostic'. Here, we review the literature addressing the prospective value of these biomarkers.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?